The Relationship of Hypertension in the Elderly to AD, Vascular Dementia, and Cognitive Function by Posner, Holly B. et al.
linked to chromosome 17q21-22 (FTDP-17): Duke family 1684.
J Neuropathol Exp Neurol 1999;58:859–866.
22. Murrell JR, Spillantini MG, Zolo P, et al. Tau gene mutation
G389R causes a tauopathy with abundant Pick body-like in-
clusions and axonal deposits. J Neuropathol Exp Neurol 1999;
58:1207–1226.
23. van Swieten JC, Stevens M, Rosso SM, et al. Phenotypic vari-
ation in hereditary frontotemporal dementia with tau muta-
tions. Ann Neurol 1999;46:617–626.
24. Arima K, Kowalska A, Hasegawa M, et al. Two brothers with
frontotemporal dementia and parkinsonism with an N279K
mutation of the tau gene. Neurology 2000;54:1787–1795.
25. Tolnay M, Spillantini MG, Rizzini C, et al. A new case of fronto-
temporal dementia and parkinsonism resulting from an intron
10  3-splice site mutation in the tau gene: clinical and patho-
logical features. Neuropathol Appl Neurobiol 2000;26:368–378.
26. Yasuda M, Takamatsu J, D’Souza I, et al. A novel mutation at
position 12 in the intron following exon 10 of the tau gene in
familial frontotemporal dementia (FTD-Kumamoto). Ann
Neurol 2000;47:422–429.
27. Spillantini MG, Goedert M, Crowther RA, et al. Familial mul-
tiple system tauopathy with presenile dementia: a disease
with abundant neuronal and glial filaments. Proc Natl Acad
Sci USA 1997;94:4113–4118.
28. Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia
and parkinsonism linked to chromosome 17: a new group of
tauopathies. Brain Pathol 1998;8:387–402.
29. Spillantini MG, Yoshida H, Rizzini C, et al. A novel tau muta-
tion (N296N) in familial dementia with swollen achromatic
neurons and corticobasal inclusion bodies. Ann Neurol 2000;
48:939–943.
30. Rizzini C, Goedert M, Hodges JR, et al. Tau gene mutation
K257T causes a tauopathy similar to Pick’s disease. J Neuro-
pathol Exp Neurol 2000;59:990–1001.
31. Spillantini MG, Crowther RA, Goedert M. Comparison of the
neurofibrillary pathology in Alzheimer’s disease and familial
dementia with tangles. Acta Neuropathol 1996;92:42–48.
32. Feany MB, Dickson DW. Widespread cytoskeletal pathology
characterizes corticobasal degeneration. Am J Pathol 1995;
146:1388–1396.
The relationship of hypertension in the
elderly to AD, vascular dementia, and
cognitive function
H.B. Posner, MD; M.-X. Tang, PhD; J. Luchsinger, MD; R. Lantigua, MD; Y. Stern, PhD; and
R. Mayeux, MD
Abstract—Background: Hypertension at the age of 45 to 50 years may predispose to AD later in life. It is not known
whether hypertension after age 65 years also contributes to AD risk, and its effect on cognitive function is also not fully
understood. Methods: Data were analyzed from 1,259 Medicare recipients free of dementia in a longitudinal study covering
a 7-year period (1991 to 1998). The effect of hypertension was first examined in relationship to the risk for incident AD
and then to incident vascular dementia (VaD) using Cox proportional hazards models. Changes in performance over time
on tasks of memory, language, and visuospatial/cognitive function were compared in those with and without hypertension
using generalized estimating equations. Results: Of the 1,259 subjects, 731 (58.1%) had a history of hypertension associ-
ated with diabetes, stroke, and heart disease. A history of hypertension was not associated with an increased risk for AD
(rate ratio [RR] 0.9, 95% CI 0.7 to 1.3) but was associated with an increased risk for VaD (1.8 [1.0 to 3.2]). Hypertension
was not associated with changes in memory, language, and general cognitive function in normal individuals over time.
Compared with individuals with neither hypertension nor heart disease, those with hypertension or heart disease alone
had no increase in risk for VaD. However, when both were present, there was a threefold increase in risk for VaD. A
sixfold increase in risk was observed when both hypertension and diabetes were present. Conclusions: Hypertension after
age 65 years is not associated with AD and does not adversely affect memory, language, or general cognitive function. A
history of hypertension may be an antecedent to VaD, particularly in the presence of heart disease or diabetes.
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Hypertension has been associated with the later de-
velopment of AD and vascular dementia (VaD),1-6
though this is disputed.7 Hypertension is thought to
act over years by decreasing the elasticity of vessels,
increasing resistance, and reducing responsiveness
to momentary changes in tissue demands.3,8,9 Athero-
sclerosis is one of the mechanisms that give rise to
increased vascular wall tension. Atherosclerosis, mea-
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sured directly by carotid ultrasound, may be related to
peripheral blood pressure and has been associated with
both AD and VaD.10 Because hypertension is frequent
in the elderly, we hypothesized that it might also be a
risk factor for AD or VaD.
Methods. Study population. Data were derived from
participants in the Washington Heights–Inwood Columbia
Aging Project identified from a random sample of healthy
Medicare beneficiaries 65 years or older residing in north-
ern Manhattan between 1991 and 1996. The sampling pro-
cedures have been described elsewhere.11 Participants
underwent an in-person, structured interview of health
and function at the time of study entry, followed by a
standard medical history, physical and neurologic exami-
nation, and neuropsychological battery. Participants were
followed at approximately 18-month intervals, repeating
the evaluations used at baseline at each follow-up. Only
individuals who completed at least one follow-up were in-
cluded in the analyses.
Of the 2,126 individuals who underwent baseline as-
sessment, 327 (15.4%) were demented and excluded from
the subsequent analysis. Data were not available for 540
(25.4%) of the cohort: 142 (6.7%) died before follow-up, 396
(18.9%) either refused further involvement with the study
or moved out of the area, and 2 (0.09%) had missing hyper-
tension history data. These 540 individuals were similar to
the study sample in sex, education, distribution of APOE
genotype, and frequency of a history of stroke, hyperten-
sion, and smoking. Those who remained in the study were
younger: 75.7 vs 77.0 years old (p  0.001). There were
also more Hispanics than whites or African Americans
remaining in the study. Those who remained were less
likely to have diabetes (13.3% vs 20.2%; p  0.0005) or
heart disease (21.8% vs 26.0%; p  0.05). The remaining
sample included 1,259 (59.2%) that were available for lon-
gitudinal analysis. The Columbia University Institutional
Review Board reviewed and approved this project. All indi-
viduals provided written informed consent.
Clinical assessments. Physicians completed standard-
ized medical and neurologic histories and examinations,
and subjects underwent a standardized neuropsychological
test battery testing multiple domains in either Spanish or
English. Orientation was evaluated using parts of the
modified Mini-Mental State Examination.12 Language was
assessed using the Boston Naming Test,13 the Controlled
Word Association test,14 category naming, and the Com-
plex Ideational Material and Phrase Repetition subtests of
the Boston Diagnostic Aphasia Evaluation.15 Abstract rea-
soning was tested using the Abstract Reasoning and Simi-
larities subtests from the Wechsler Adult Intelligence
Scale–Revised (WAIS-R),16 the nonverbal Identities and
Oddities subtest of the Mattis Dementia Rating Scale,17
the Rosen Drawing Test,18 and a matching version of the
Benton Visual Retention Test.19 Memory was evaluated
using the multiple-choice version of the Benton Visual Re-
tention Test19 and seven subtests of the Selective Remind-
ing Test20: total recall, long-term recall, long-term storage,
continuous long-term storage, words recalled on last trial,
delayed recall, and delayed recognition. This neuropsycho-
logical battery had been validated in the same geographic
area.21,22
Results of these examinations were reviewed by a group
of physicians and neuropsychologists who reached consen-
sus regarding the presence or absence of dementia using
published criteria for probable and possible AD23 and
VaD.24 Severity of AD was rated using the Clinical Demen-
tia Rating Scale (CDR).25 Only those individuals with CDR
scores of 1.0 were considered as cases for the initial anal-
yses. Individuals who had CDR ratings of 0.5 remained
in the comparison group.
Brain imaging was available in 85% of cases with a
history of stroke; in the remainder, stroke was defined by
World Health Organization criteria.26 Subjects without de-
mentia at baseline, but with stroke, were included in the
analyses.
Ethnic group. At baseline, ethnic group was docu-
mented by self-report using the format of the 1990 US
Census.27 Individuals were first asked to indicate their
racial group and then whether or not they were of “Hispan-
ic origin.”
Hypertension. At baseline, all participants were asked
whether or not they had a history of hypertension (high
blood pressure) at any time during their life. If affirmative,
they were asked whether or not they were under treat-
ment and the specific type of treatment. Blood pressure
was also recorded at each visit using the Dinamap Pro 100
(Critikon Co., Tampa, FL). The blood pressure cuff was
placed on the right arm while the individual was seated,
and a recording was obtained every 3 minutes over 9 min-
utes. The third measurement was recorded in the data-
base. Values above 140 mm Hg (systolic) and 90 mm Hg
(diastolic) were used as criteria for hypertension.28 For an-
alytic purposes, we reclassified measured blood pressure
using the guidelines suggested in the Sixth Report of the
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure.29
Other medical information. At the baseline interview,
all participants received a standardized interview concern-
ing a history of medical illnesses (e.g., diabetes, cancer) at
any time during their lives. If affirmative, they were asked
about the type of treatment received.
APOE genotype. Genotypes were obtained by amplifi-
cation of genomic DNA with PCR subjected to CfoI restric-
tion analysis using APOE primers and conditions similar
to those described by Hixson and Vernier30 and modified by
Maestre et al.31
Data analysis. Continuous variables were compared
using analysis of variance, and categorical variables were
compared using 2 tests. Cox regression models were used
with the exposure being a history of hypertension and the
outcome either AD or VaD. Patients who met criteria for
possible AD with a history of stroke were classified as
possible AD for the analyses regarding AD and as VaD for
the studies regarding that outcome. Baseline information
was used for all covariates including age, education, and a
history of diabetes or heart disease. Heart disease was
defined as a history of myocardial infarction, congestive
heart failure, or angina. For these regression analyses, we
set   0.05 and   0.20. With a fixed sample size of
1,259, the exposure of hypertension and the confounders of
diabetes and heart disease, the lowest detectable risk ratio
(RR) for AD was 1.68 and for VaD 2.5. To assess for effect
modification by other vascular diseases, dummy variables
were created and used in Cox regression models.
A factor analysis was performed using data from the
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entire cohort with the 15 neuropsychological measures us-
ing a principal component analysis with varimax rotation
and Kaiser normalization.32 This analysis yielded three
factors: 1) a memory factor, where the seven subtests of
the Selective Reminding Test were the main contributors;
2) a visuospatial/cognitive factor, in which visuospatial and
tests of reasoning were the main contributors; and 3) a
language factor, where language measures from the Bos-
ton Naming Test,13 Controlled Oral Word Association
test,14 and the WAIS-R Similarities16 were the main con-
tributors. Component scores for each participant at each
visit were calculated by adding the scores of the measures
that contributed most to each factor. Each factor score was
normally distributed (skewness: memory 0.8, language
0.6, visuospatial/cognitive 0.7).
Generalized estimation equations (GEE)33 were used to
examine changes in each neuropsychological domain over
time. The dependent variables were the factor scores, and
the independent variables were baseline history of hyper-
tension and time, included as a continuous variable. The
GEE analyses yield  values that represent the strength of
the associations between factor scores and variables in-
cluded in the model. A significant group effect indicates a
difference between two groups at the baseline or at any
subsequent interval. A positive value for  indicates that
the group with a specific variable performed better than
the group without that variable. A significant time effect
indicates a change in a factor score over the total duration
of follow-up. A significant interaction effect indicates a
difference in the rate of change in a factor score depending
on the presence of the covariate.
Results. Of the initial 1,259 participants, 731 (58.1%)
reported a history of hypertension at baseline. Compared
with individuals without hypertension, those with hyper-
tension were more likely to report a history of heart dis-
Table 1 Baseline characteristics of individuals who did and did not develop dementia





n 157 56 1,043
Age (SD), y 79.3 (6.7) 77.9 (6.2) 75.0 (5.6)
Education (SD), y 7.1 (4.5) 8.2 (4.4) 8.9 (4.6)
Sex
Women, n  868, n (%) 108 (12.4) 41 (4.7) 721 (83.1)
Men, n  391, n (%) 49 (12.5) 15 (3.8) 322 (82.4)
Ethnic group
African American, n  408, n (%) 62 (15.2) 22 (5.4) 328 (80.4)
Hispanic, n  560, n (%) 71 (12.7) 25 (4.5) 458 (81.8)
White, n  282, n (%) 23 (8.2) 9 (3.2) 249 (88.3)
Other, n  9, n (%) 1 (11.1) 0 8 (88.9)
APOE-4 genotype, % 32.9 31.9 27.1
Heart disease, % 29.9 35.7* 28.4
Diabetes, % 21.7 41.4* 18.9
Hypertension, % 54.5 69.9 57.9
Stroke, % 10.3 100 8.1
Never smoked, % 56.4 55.3 50.1
Past smoker, % 25.6 31.9 34.6
Current smoker, % 18.0 12.6 15.3
Nineteen patients with other dementia are not shown. There is overlap in the vascular dementia category as 16 patients met criteria
for possible AD and vascular dementia. Their data are included in both columns and analyses.
* p  0.05.
Table 2 Proportional hazards model to assess risk for AD or vascular dementia (VaD) by history of hypertension
Hypertension Total at risk Developed AD, n (%) AD, RR (95% CI) Developed VaD, n (%) VaD, RR (95% CI)
Present 731 84 (11.5) 0.9 (0.7–1.3) 39 (5.3) 1.8 (1.0–3.2)*
Absent 528 73 (13.8) 1.0 (reference) 17 (3.2) 1.0 (reference)
Unadjusted risk ratio (RR) and 95% CI are shown. When AD model was repeated adjusting for age, education, ethnic group, and his-
tory of heart disease, the RR decreased to 0.8 (95% CI, 0.6–1.1). Similarly, the RR decreased to 1.6 (0.9–2.9) for the VaD model when it
was adjusted for these factors. The RR did not change when stratified by treatment.
* p  0.05.
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ease (13.5% vs 27.8%; p  0.0001), diabetes (15% vs 23.9%;
p  0.0001), or stroke (7.3% vs 12.8%; p  0.006). Those
without hypertension more frequently were smokers than
those with hypertension (19.1% vs 12.8%; p  0.01).
A history of hypertension was validated by direct mea-
surement of blood pressure. The average systolic blood
pressure for those without a history of hypertension was
143 mm Hg and diastolic 73 mm Hg, whereas those with a
history of hypertension, either treated or untreated, had
average blood pressures of 154 mm Hg systolic and 78 mm
Hg diastolic. With use of the criteria for hypertension,28
the sensitivity and specificity were 76 and 48% for systolic
hypertension and 85 and 35% for diastolic hypertension.
The values for sensitivity and specificity did not differ for
those with and without AD.
Over the 7 years of follow-up, AD developed in 157
(12.5%) of the 1,259 participants. The proportion of males
and females who developed AD was similar, but AD was
more frequent in African Americans than Hispanics or
whites. Compared with those who remained free of demen-
tia, those who developed AD had fewer years of education.
At baseline, neither a history of hypertension, diabetes,
heart disease, or stroke nor the presence of the APOE-4
genotype differentiated who would develop AD with CDR
of 	1 (table 1).
VaD developed in 56 (4.4%) of the 1,259 study partici-
pants during the 7 years of follow-up. The proportion of
males and females who developed VaD was similar, as
were the proportion of whites, African Americans, and His-
panics, though the numbers in each group were small.
Compared with those who remained free of dementia,
those with a baseline history of heart disease or diabetes
were more likely to develop VaD. Neither age nor the pres-
ence of the APOE-4 genotype nor prior smoking history
differentiated who would develop VaD (see table 1).
A history of hypertension was not associated with an
increased risk for AD (table 2). The incidence rate of AD
without a history of hypertension was 2.9%/person-year,
and with a history of hypertension it was 3.1%/person-
year. Adjustment for age, education, heart disease, and
ethnic group had no effect on the relationship. No additive
or synergistic effects were found between hypertension and
other vascular risk factors and the relationship to AD risk.
Treatment of hypertension did not affect risk estimates for
AD (no treatment: RR 0.96, 95% CI 0.6 to 1.5; treated:
0.86, 0.6 to 1.2).
The incidence of VaD among those without a history of
hypertension was 4.2%/person-year, but with a history of
hypertension, it increased to 8.6%. Compared with those
without hypertension, the relative risk for VaD among per-
sons with a history of hypertension was nearly twofold
higher (see table 2). Adjustments for age, education, sex,
ethnicity, APOE-4 status, and history of heart disease or
smoking diminished this relationship (see table 2). Treat-
ment of hypertension again did not affect risk estimates
for VaD (no treatment: RR 1.7, 95% CI 0.8 to 3.6; treated:
1.7, 0.9 to 3.2). We repeated this analysis, excluding pa-
tients with AD and stroke classified as VaD, and the RR
increased (RR 2.1, 95% CI 1.0 to 4.6, p  0.05). Adjustment
for confounders, diabetes, and heart disease again de-
creased the association (RR 1.8, 95% CI 0.8 to 3.9). Diabe-
tes was strongly associated with VaD (RR 2.7, 95% CI 1.3
to 5.6, p  0.007) in the model.
The sensitivity and specificity for a history of hyperten-
sion were 76 and 48% (systolic hypertension) and 85 and
35% (diastolic hypertension). We analyzed the association
between hypertension and dementia in two ways. Using
the classification of high blood pressure suggested by the
Sixth Report of the National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure,29 we examined the baseline systolic and diastolic
blood pressure measurements. There was no relationship





Developed AD Developed VaD Developed AD or VaD
n (%) RR (95% CI) n (%) RR (95% CI) n (%) RR (95% CI)
SBP
Normal 130 171 27 (15.8) 1.0 (reference) 6 (3.5) 1.0 (reference) 30 (17.5) 1.0 (reference)
High–normal 130–139 245 27 (11.0) 0.8 (0.5–1.3) 10 (4.1) 1.3 (0.5–3.5) 34 (13.9) 0.9 (0.5–1.4)
Stage 1 140–159 440 50 (11.4) 0.8 (0.5–1.2) 21 (4.8) 1.4 (0.5–3.4) 63 (14.3) 0.9 (0.6–1.3)
Stage 2 160–179 220 29 (13.2) 0.8 (0.5–1.3) 6 (2.7) 0.8 (0.2–2.3) 33 (15.0) 0.8 (0.5–1.3)
Stage 3 180 133 18 (13.5) 0.8 (0.4–1.4) 9 (6.8) 1.7 (0.6–4.8) 23 (17.3) 0.9 (0.5–1.5)
DBP
Normal 85 906 113 (12.5) 1.0 (reference) 35 (3.9) 1.0 (reference) 134 (14.8) 1.0 (reference)
High–normal 85–89 116 19 (16.4) 1.1 (0.7–1.8) 3 (2.6) 0.6 (0.2–2.0) 21 (18.1) 1.1 (0.7–1.7)
Stage 1 90–99 115 11 (9.6) 0.7 (0.4–1.4) 8 (7.0) 1.8 (0.8–4.0) 15 (13.0) 0.9 (0.5–1.5)
Stage 2 100–109 41 2 (4.9) 0.3 (0.1–1.4) 1 (2.4) 0.6 (0.1–4.6) 3 (7.3) 0.4 (0.1–1.4)
Stage 3 110 30 6 (20.0) 1.8 (0.8–4.0) 5 (16.7) 4.6 (1.8–11.9)* 10 (33.3) 2.5 (1.3–4.7)†
Direct measurement of blood pressure was classified by the Sixth Report of the National Committee on Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure.29
* p  0.001.
† p  0.006.
RR  rate ratio; SBP  systolic blood pressure; DBP  diastolic blood pressure.
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between any stage of high blood pressure and either AD or
VaD, with a single exception. A relationship between mea-
sured diastolic blood pressure values of 110 mm Hg and
incident VaD was found (RR 4.6, 95% CI 1.8 to 11.9, p 
0.001) (table 3). However, there were only 30 individuals
who had diastolic blood pressure values of 110 mm Hg,
and only 5 of these developed VaD. Because many individ-
uals reported both hypertension and other vascular dis-
eases, we also investigated the independent and joint
effects of hypertension and other vascular-related disor-
ders on either AD or VaD (tables 4 and 5). Compared with
individuals without hypertension or other vascular disor-
ders, there was no increased risk for either AD or VaD
among those with hypertension, heart disease, or diabetes.
However, when hypertension and heart disease were re-
ported together, the risk for VaD was greatly increased
(RR 3.3, 95% CI 1.7 to 6.6, p  0.0007). The joint effects of
diabetes and hypertension on VaD risk were also greatly
increased (RR 6.2, 95% CI 2.9 to 13.5, p  0.0001). There
was only a weak joint effect of hypertension and diabetes
on AD risk.
GEE analysis in those without dementia revealed that
the presence or absence of hypertension did not influence
memory, language, or cognition performance over the
follow-up period. The differences in slope were 0.19 (3.2
to 3.6; p  0.46) for memory, 0.10 (0.14 to 0.35; p  0.41)
for language, and 0.45 (0.88 to 1.8; p  0.51) for general
cognition.
Discussion. This prospective study of 1,259 partici-
pants over 7 years found no association between a his-
tory of hypertension and the development of AD. When
hypertension was classified using measured blood pres-
sure, no evidence of association with AD existed. More-
over, hypertension did not affect memory, language, or
general cognitive function over time.
Though there was an association between hyper-
tension and VaD, it was weak and may have been
confounded by other variables. A significant relation-
ship was found only when the diastolic blood pres-
sure exceeded 110 mm Hg, which occurred in only a
small number of individuals. Although it is possible
that this finding was the result of a type 1 error from
multiple comparisons, the association reached signif-
icance even after Bonferroni correction for 12 subcat-
egories of high blood pressure (p  0.004). The RR
for the other categories of measured diastolic and
systolic blood pressures were not consistent. None-
theless, a weak association between elevated dia-
stolic blood pressure and VaD could not be excluded.
When analyzed independently and jointly, an in-
Table 4 Independent effects of history of hypertension and two vascular risk factors (heart disease and diabetes) on risk for AD
History at baseline




(95% CI)Hypertension Heart disease Diabetes
No No 370 (88) 53 (12) 1.0 (reference)
Yes No 403 (91) 38 (9) 0.9 (0.6–1.4)
No Yes 85 (83) 17 (17) 1.0 (0.6–1.8)
Yes Yes 242 (84) 46 (16) 1.3 (0.9–2.0)
No No 386 (87) 60 (13) 1.0 (reference)
Yes No 495 (89) 60 (11) 1.0 (0.7–1.5)
No Yes 69 (87) 10 (13) 1.3 (0.7–2.6)
Yes Yes 150 (86) 24 (14) 1.6 (1.0–2.6)*
* Significant at p  0.05.
Table 5 Independent effects of history of hypertension and two vascular risk factors (heart disease and diabetes) on risk for vascular
dementia (VaD)
History at baseline




(95% CI)Hypertension Heart disease Diabetes
No No 409 (97) 14 (3) 1.0 (reference)
Yes No 430 (98) 11 (2) 1.1 (0.5–2.4)
No Yes 99 (97) 3 (3) 0.8 (0.2–2.8)
Yes Yes 260 (90) 28 (10) 3.3 (1.7–6.6)*
No No 434 (97) 12 (3) 1.0 (reference)
Yes No 534 (96) 21 (4) 1.9 (0.9–4.0)
No Yes 74 (94) 5 (6) 3.2 (1.1–9.2)*
Yes Yes 156 (90) 18 (10) 6.2 (2.9–13.5)*
* Significant at p  0.05.
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teraction between hypertension and heart disease on
VaD risk was found. Concurrent diabetes and hyper-
tension appeared to have additive effects on VaD
risk. Because heart disease, diabetes, and hyperten-
sion are common ailments in the elderly, the joint
effects on the risk for VaD in the elderly need to be
further investigated. However, in the absence of
heart disease and diabetes, the relationship between
VaD and hypertension remains tenuous.
The evidence favoring an association between hy-
pertension and dementia, including AD and VaD,
has been most compelling for hypertension during
middle age.2,34-37 Perhaps this is when other vascular-
related diseases are developing and the combined
effects of these changes in the vasculature are be-
coming evident. Complications of hypertension, such
as stroke, may trigger the onset of AD,38 though our
results do not suggest the existence of an interaction
between hypertension and stroke on AD risk. Treat-
ment of hypertension may decrease AD risk in men,2
and the strength of the relationship between demen-
tia and hypertension may vary with the severity of
hypertension during middle age.4 Not all studies
have verified a relationship between hypertension
and AD.7
Skoog et al.6 found an association between hyper-
tension at age 70 years and dementia 10 to 15 years
later in a smaller cohort of 382, where 10% of the
people became demented. Two hypertension treat-
ment trials failed to reduce the incidence of cognitive
decline,39-41 though differential dropout42 or the
choice of drug may have contributed to the out-
come.43 The Canadian Study of Health and Aging44
examined 105 patients who developed VaD over 5
years and found that hypertension was a significant
risk factor only for females, but not males. Thus, it is
possible that with longer follow-up of our cohort, a
more definitive result would have emerged with re-
gard to the association between hypertension and
VaD. However, an earlier study45 using data from
this same cohort showed that only diabetes was asso-
ciated with the development of VaD and that there
was no association between traditional vascular risk
factors and AD, thereby eliminating the possibility of
confounding by these variables. Our finding of syner-
gistic or additive effects on the risk for VaD between
hypertension and either heart disease or diabetes
has not been previously described.
A study of experimental hypertension in nonhu-
man primates revealed an association between cogni-
tive and behavioral abnormalities and extravasation
from vessels with impaired blood–brain barrier func-
tion.46 Although this might also be true in humans,
the effects are acute. Further research needs to be
done to clarify the relationship between each of the
vascular risk factors and cerebral vessel dysfunction,
especially because these effects may take time to
develop.
We found no relationship between hypertension
and changes in memory, language, or general cogni-
tive function over follow-up of cognitively normal
participants. Prior studies have used less detailed
assessments of neuropsychological function3,5,47-49 or
were cross-sectional in nature.47,49,50 Our use of GEE
to evaluate longitudinal data provides the ability to
measure the slope of performance as an indictor of
change in each cognitive domain over the study pe-
riod. There were no differences in the slopes for
memory, language, and visuospatial/general cogni-
tion function in those with, compared with those
without, hypertension.
A history of hypertension at age 65 years, treated
or untreated, does not contribute to the development
of AD and does not predispose to a decline in cogni-
tion, even without the development of dementia as
people age. The association between hypertension
and VaD is weak and may be related to concurrent
vascular-related disorders so prevalent among the
elderly.
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